Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:NMTC NASDAQ:SLNO NASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.63+51.9%$0.54$0.31▼$1.80$20.53M-2.643.25 million shs24.10 million shsNMTCNeuroOne Medical Technologies$0.93+3.3%$0.83$0.40▼$1.39$46.50M0.71447,501 shs550,641 shsSLNOSoleno Therapeutics$59.21+2.1%$69.04$41.50▼$90.32$3.15B-2.752.69 million shs1.62 million shsZYXIZynex$1.47+1.4%$1.60$1.23▼$9.42$44.54M1.187,861 shs81,489 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys0.00%+75.13%+67.62%-32.20%-43.23%NMTCNeuroOne Medical Technologies0.00%+1.20%+17.31%+27.22%-2.96%SLNOSoleno Therapeutics0.00%-8.85%-15.14%-30.56%+19.30%ZYXIZynex0.00%+1.38%-1.34%-41.43%-81.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.63+51.9%$0.54$0.31▼$1.80$20.53M-2.643.25 million shs24.10 million shsNMTCNeuroOne Medical Technologies$0.93+3.3%$0.83$0.40▼$1.39$46.50M0.71447,501 shs550,641 shsSLNOSoleno Therapeutics$59.21+2.1%$69.04$41.50▼$90.32$3.15B-2.752.69 million shs1.62 million shsZYXIZynex$1.47+1.4%$1.60$1.23▼$9.42$44.54M1.187,861 shs81,489 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys0.00%+75.13%+67.62%-32.20%-43.23%NMTCNeuroOne Medical Technologies0.00%+1.20%+17.31%+27.22%-2.96%SLNOSoleno Therapeutics0.00%-8.85%-15.14%-30.56%+19.30%ZYXIZynex0.00%+1.38%-1.34%-41.43%-81.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 2.50Moderate Buy$7.331,063.84% UpsideNMTCNeuroOne Medical Technologies 2.33Hold$2.23139.25% UpsideSLNOSoleno Therapeutics 2.92Moderate Buy$115.0994.38% UpsideZYXIZynex 2.00Hold$4.90233.33% UpsideCurrent Analyst Ratings BreakdownLatest FEMY, SLNO, NMTC, and ZYXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025FEMYFemasysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NMTCNeuroOne Medical TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SLNOSoleno TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ZYXIZynexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/10/2025SLNOSoleno TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/9/2025NMTCNeuroOne Medical TechnologiesMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.008/27/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$106.008/20/2025SLNOSoleno TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$123.008/18/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.00 ➝ $110.008/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.008/7/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.89M10.88N/AN/A$0.10 per share6.30NMTCNeuroOne Medical Technologies$3.45M13.48N/AN/A$0.03 per share31.00SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/AZYXIZynex$192.35M0.23$0.24 per share6.02$1.12 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.86N/AN/AN/A-1,113.72%-713.74%-152.60%11/11/2025 (Estimated)NMTCNeuroOne Medical Technologies-$12.32M-$0.15N/A∞N/A-55.44%-163.49%-78.67%12/16/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)ZYXIZynex$2.99M-$0.94N/A3.13N/A-19.79%-78.54%-16.70%10/30/2025 (Estimated)Latest FEMY, SLNO, NMTC, and ZYXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025ZYXIZynex-$0.19N/AN/AN/A$22.71 millionN/A8/14/2025Q3 2025NMTCNeuroOne Medical Technologies-$0.05-$0.03+$0.02-$0.03$1.82 million$1.70 million8/8/2025Q2 2025FEMYFemasys-$0.18-$0.16+$0.02-$0.16$0.80 million$0.41 million8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.030.890.41NMTCNeuroOne Medical TechnologiesN/A7.135.80SLNOSoleno Therapeutics0.2115.1315.01ZYXIZynex0.560.620.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%NMTCNeuroOne Medical Technologies16.07%SLNOSoleno Therapeutics97.42%ZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%NMTCNeuroOne Medical Technologies8.90%SLNOSoleno Therapeutics6.40%ZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3032.58 million28.82 millionNot OptionableNMTCNeuroOne Medical Technologies2050.00 million45.55 millionOptionableSLNOSoleno Therapeutics3053.15 million49.74 millionOptionableZYXIZynex77030.30 million15.37 millionOptionableFEMY, SLNO, NMTC, and ZYXI HeadlinesRecent News About These CompaniesReviewing Zynex (NASDAQ:ZYXI) & Resonate Blends (OTCMKTS:KOAN)September 30, 2025 | americanbankingnews.comZYNEX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 27, 2025 | globenewswire.comZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 9, 2025 | globenewswire.comZynex announces new executive teamAugust 18, 2025 | msn.comZynex welcomes Steve Dyson as CEO, adds to leadership teamAugust 18, 2025 | proactiveinvestors.comZynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key RolesAugust 18, 2025 | prnewswire.comZynex, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 14, 2025 | globenewswire.comZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmAugust 13, 2025 | globenewswire.comZynex Q2 Revenue Drops 55%August 5, 2025 | fool.comZynex Inc. Faces Challenges Amid Strategic ShiftsAugust 4, 2025 | theglobeandmail.comZynex, Inc. (NASDAQ:ZYXI) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | msn.comHC Wainwright & Co. Downgrades Zynex (ZYXI)August 1, 2025 | msn.comZynex, Inc.: Zynex Reports Second Quarter 2025 Financial ResultsAugust 1, 2025 | finanznachrichten.deZynex Inc (ZYXI) Q2 2025 Earnings Report Preview: What to Look ForAugust 1, 2025 | finance.yahoo.comZynex, Inc. (ZYXI) Q2 2025 Earnings Call TranscriptJuly 31, 2025 | seekingalpha.comZynex Inc. (ZYXI) Reports Q2 Loss, Misses Revenue EstimatesJuly 31, 2025 | zacks.comZynex eyes growth revival under new CEO, advances oximeter technologyJuly 31, 2025 | proactiveinvestors.comZynex Reports Second Quarter 2025 Financial ResultsJuly 31, 2025 | prnewswire.comZynex Sets Second Quarter 2025 Earnings CallJuly 22, 2025 | prnewswire.comZynex: New CEO Steven Dyson shares his vision – ICYMIJuly 12, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFEMY, SLNO, NMTC, and ZYXI Company DescriptionsFemasys NASDAQ:FEMY$0.63 +0.22 (+51.87%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.82 +0.19 (+30.30%) As of 09:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.NeuroOne Medical Technologies NASDAQ:NMTC$0.93 +0.03 (+3.33%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.98 +0.05 (+5.38%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Soleno Therapeutics NASDAQ:SLNO$59.21 +1.23 (+2.12%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$60.07 +0.86 (+1.45%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Zynex NASDAQ:ZYXI$1.47 +0.02 (+1.38%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.48 +0.02 (+1.02%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
